Clinical Trial Update: Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immune response of the dengue virus vaccine candidate rDEN4delta30-200,201 in healthy adults; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• rDEN4delta30-200,201 dengue vaccine candidate (Dengue virus vaccine (rDEN4Δ30-200,201))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue Fever | Phase 1 | Status: COMPLETED